Research programme: matrix metalloproteinase inhibitors - Shionogi
Alternative Names: MMI 116; MMI-166Latest Information Update: 20 Aug 2010
At a glance
- Originator Shionogi
- Class Sulfonamides
- Mechanism of Action Matrix metalloproteinase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Osteoarthritis; Solid tumours
Most Recent Events
- 31 Dec 2004 Preclinical trials in Osteoarthritis in Japan (unspecified route)
- 16 Apr 2004 Data presented at the 95th Annual Meeting of the American Association for Cancer Research (AACR-2004) have been added to the Cancer pharmacodynamics section
- 30 Oct 2002 Preclinical trials in Solid tumours in Japan (unspecified route)